دورية أكاديمية
Placebo Control and Blinding in Randomized Trials of Procedural Interventions ; A Systematic Review and Meta-Regression
| العنوان: | Placebo Control and Blinding in Randomized Trials of Procedural Interventions ; A Systematic Review and Meta-Regression |
|---|---|
| المؤلفون: | Rajkumar, Christopher A., Thomas, Katharine E., Foley, Michael, Ganesananthan, Sashiananthan, Evans, Holli, Simader, Florentina, Syam, Sharan, Nour, Daniel, Beattie, Catherine, Khan, Caitlin, Reddy, Rohin K., Ahmed-Jushuf, Fiyyaz, Francis, Darrel P., Shun-Shin, Matthew, Al-Lamee, Rasha K. |
| المصدر: | JAMA Surgery ; ISSN 2168-6254 |
| بيانات النشر: | American Medical Association (AMA) |
| سنة النشر: | 2024 |
| الوصف: | Importance Unlike medications, procedural interventions are rarely trialed against placebo prior to becoming accepted in clinical practice. When placebo-controlled trials are eventually conducted, procedural interventions may be less effective than previously believed. Objective To investigate the importance of including a placebo arm in trials of surgical and interventional procedures by comparing effect sizes from trials of the same procedure that do and do not include a placebo arm. Data Sources Searches of MEDLINE and Embase identified all placebo-controlled trials for procedural interventions in any specialty of medicine and surgery from inception to March 31, 2019. A secondary search identified randomized clinical trials assessing the same intervention, condition, and end point but without a placebo arm for paired comparison. Study Selection Placebo-controlled trials of anatomically site-specific procedures requiring skin incision or endoscopic techniques were eligible for inclusion; these were then matched to trials without placebo control that fell within prespecified limits of heterogeneity. Data Extraction and Synthesis Random-effects meta-regression, with placebo and blinding as a fixed effect and intervention and end point grouping as random effects, was used to calculate the impact of placebo control for each end point. Data were analyzed from March 2019 to March 2020. Main Outcomes and Measures End points were examined in prespecified subgroups: patient-reported or health care professional–assessed outcomes, quality of life, pain, blood pressure, exercise-related outcomes, recurrent bleeding, and all-cause mortality. Results Ninety-seven end points were matched from 72 blinded, placebo-controlled trials (hereafter, blinded) and 55 unblinded trials without placebo control (hereafter, unblinded), including 111 500 individual patient end points. Unblinded trials had larger standardized effect sizes than blinded trials for exercise-related outcomes (standardized mean difference [SMD], 0.59; 95% CI, ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1001/jamasurg.2024.0718 |
| الإتاحة: | https://doi.org/10.1001/jamasurg.2024.0718Test https://jamanetwork.com/journals/jamasurgery/articlepdf/2817650/jamasurgery_rajkumar_2024_oi_240017_1712703857.74164.pdfTest |
| رقم الانضمام: | edsbas.204A153E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamasurg.2024.0718 |
|---|